Surrozen, Inc. (NASDAQ:SRZN) CFO Sells $20,513.97 in Stock

Surrozen, Inc. (NASDAQ:SRZN) CFO Charles O. Williams sold 1,181 shares of Surrozen stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $17.37, for a total transaction of $20,513.97. Following the transaction, the chief financial officer now owns 8,982 shares in the company, valued at $156,017.34. This represents a 11.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Surrozen Stock Performance

Shares of SRZN traded down $2.79 during mid-day trading on Monday, reaching $14.23. The stock had a trading volume of 197,851 shares, compared to its average volume of 168,984. Surrozen, Inc. has a 12 month low of $6.00 and a 12 month high of $18.17. The business has a fifty day moving average of $10.92 and a 200 day moving average of $9.90.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.77) by $2.33. The business had revenue of $10.00 million for the quarter. Equities analysts forecast that Surrozen, Inc. will post -7.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Guggenheim raised Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday.

Institutional Investors Weigh In On Surrozen

Several large investors have recently bought and sold shares of the business. Armistice Capital LLC bought a new position in shares of Surrozen in the 2nd quarter valued at about $2,080,000. CVI Holdings LLC purchased a new position in Surrozen during the second quarter worth $711,000. Nantahala Capital Management LLC bought a new position in Surrozen during the second quarter valued at $2,050,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Surrozen in the second quarter valued at $724,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.